Syros Pharmaceuticals (NASDAQ:SYRS) Earns Sell Rating from Analysts at StockNews.com

Investment analysts at StockNews.com assumed coverage on shares of Syros Pharmaceuticals (NASDAQ:SYRS) in a research report issued to clients and investors on Thursday. The brokerage set a “sell” rating on the stock.

SYRS has been the topic of a number of other research reports. TD Cowen reaffirmed a “hold” rating on shares of Syros Pharmaceuticals in a research note on Wednesday, November 13th. HC Wainwright restated a “neutral” rating and issued a $1.00 target price (down previously from $6.00) on shares of Syros Pharmaceuticals in a report on Wednesday, November 13th. JMP Securities restated a “market perform” rating on shares of Syros Pharmaceuticals in a report on Wednesday, November 13th. Finally, Brookline Capital Management reaffirmed a “hold” rating on shares of Syros Pharmaceuticals in a research note on Wednesday, November 13th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and one has assigned a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $3.33.

Syros Pharmaceuticals Price Performance

Shares of NASDAQ:SYRS opened at $0.08 on Thursday. The company’s 50 day simple moving average is $0.18 and its 200 day simple moving average is $0.92. The stock has a market capitalization of $2.26 million, a price-to-earnings ratio of -0.03 and a beta of 1.31. Syros Pharmaceuticals has a 1 year low of $0.07 and a 1 year high of $6.93.

Institutional Trading of Syros Pharmaceuticals

A number of institutional investors have recently modified their holdings of SYRS. Two Sigma Securities LLC bought a new position in shares of Syros Pharmaceuticals in the 4th quarter worth $25,000. GSA Capital Partners LLP bought a new stake in shares of Syros Pharmaceuticals during the 3rd quarter valued at about $34,000. Finally, Exome Asset Management LLC boosted its stake in shares of Syros Pharmaceuticals by 87.6% during the 3rd quarter. Exome Asset Management LLC now owns 298,575 shares of the company’s stock valued at $642,000 after purchasing an additional 139,400 shares in the last quarter. 91.47% of the stock is currently owned by hedge funds and other institutional investors.

Syros Pharmaceuticals Company Profile

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.